Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Medical Oncology | 38 | 2025 | 2341 | 4.710 |
Why?
|
Breast Neoplasms | 91 | 2024 | 21206 | 3.360 |
Why?
|
Neoplasms | 67 | 2025 | 22365 | 2.850 |
Why?
|
Informed Consent | 10 | 2022 | 1010 | 1.640 |
Why?
|
Cytochrome P-450 CYP2D6 | 8 | 2016 | 108 | 1.560 |
Why?
|
Tamoxifen | 10 | 2016 | 966 | 1.140 |
Why?
|
Cost of Illness | 10 | 2025 | 1951 | 1.110 |
Why?
|
Health Expenditures | 10 | 2025 | 2389 | 1.100 |
Why?
|
Quality of Life | 32 | 2024 | 13489 | 1.090 |
Why?
|
Early Detection of Cancer | 6 | 2022 | 3237 | 0.990 |
Why?
|
Antineoplastic Agents, Hormonal | 16 | 2024 | 1536 | 0.970 |
Why?
|
Exercise Therapy | 10 | 2023 | 939 | 0.960 |
Why?
|
Health Care Costs | 11 | 2023 | 3239 | 0.940 |
Why?
|
Clinical Trials as Topic | 16 | 2024 | 8052 | 0.910 |
Why?
|
Biological Specimen Banks | 2 | 2019 | 788 | 0.870 |
Why?
|
Ethics Consultation | 1 | 2022 | 59 | 0.780 |
Why?
|
Biopsy | 12 | 2024 | 6786 | 0.750 |
Why?
|
Music | 1 | 2023 | 247 | 0.720 |
Why?
|
Sleep Initiation and Maintenance Disorders | 2 | 2020 | 1107 | 0.720 |
Why?
|
Neoplasm Recurrence, Local | 13 | 2024 | 9412 | 0.700 |
Why?
|
Medical Assistance | 2 | 2017 | 108 | 0.670 |
Why?
|
Humans | 190 | 2025 | 767991 | 0.650 |
Why?
|
Chemotherapy, Adjuvant | 20 | 2024 | 3553 | 0.630 |
Why?
|
Therapies, Investigational | 2 | 2010 | 110 | 0.630 |
Why?
|
Tissue Banks | 1 | 2019 | 183 | 0.610 |
Why?
|
Mastectomy, Segmental | 6 | 2020 | 974 | 0.590 |
Why?
|
Fear | 4 | 2024 | 1495 | 0.590 |
Why?
|
Teaching Rounds | 1 | 2022 | 282 | 0.590 |
Why?
|
Mass Screening | 5 | 2022 | 5458 | 0.590 |
Why?
|
Health Care Rationing | 3 | 2021 | 435 | 0.590 |
Why?
|
Patients | 6 | 2021 | 908 | 0.560 |
Why?
|
Female | 118 | 2025 | 397113 | 0.530 |
Why?
|
Health Services Needs and Demand | 3 | 2020 | 1406 | 0.520 |
Why?
|
Cost-Benefit Analysis | 10 | 2022 | 5536 | 0.520 |
Why?
|
Exercise | 7 | 2021 | 5955 | 0.500 |
Why?
|
Biomedical Research | 9 | 2025 | 3463 | 0.490 |
Why?
|
Drug Costs | 4 | 2019 | 1195 | 0.490 |
Why?
|
Health Knowledge, Attitudes, Practice | 8 | 2016 | 4055 | 0.480 |
Why?
|
Physician-Patient Relations | 8 | 2024 | 3269 | 0.470 |
Why?
|
Insurance, Health | 3 | 2017 | 2517 | 0.460 |
Why?
|
Survivors | 12 | 2023 | 2381 | 0.460 |
Why?
|
Nurse Practitioners | 1 | 2017 | 271 | 0.450 |
Why?
|
Patient Preference | 2 | 2019 | 946 | 0.440 |
Why?
|
Antineoplastic Agents | 10 | 2021 | 13658 | 0.440 |
Why?
|
Decision Making | 7 | 2024 | 3952 | 0.420 |
Why?
|
Autoimmune Diseases | 1 | 2025 | 2256 | 0.410 |
Why?
|
Physicians, Primary Care | 1 | 2019 | 624 | 0.400 |
Why?
|
Pharmacogenetics | 2 | 2014 | 682 | 0.400 |
Why?
|
Clinical Trials, Phase II as Topic | 2 | 2024 | 639 | 0.400 |
Why?
|
Selective Estrogen Receptor Modulators | 2 | 2009 | 131 | 0.400 |
Why?
|
Continuity of Patient Care | 1 | 2019 | 1078 | 0.390 |
Why?
|
Tissue Extracts | 1 | 2012 | 139 | 0.380 |
Why?
|
Practice Guidelines as Topic | 8 | 2019 | 7445 | 0.380 |
Why?
|
Ethics, Medical | 3 | 2022 | 785 | 0.380 |
Why?
|
Attitude of Health Personnel | 7 | 2019 | 3929 | 0.380 |
Why?
|
Emotions | 2 | 2023 | 2766 | 0.380 |
Why?
|
Middle Aged | 65 | 2025 | 223422 | 0.370 |
Why?
|
Cross-Sectional Studies | 15 | 2025 | 26375 | 0.370 |
Why?
|
Adult | 66 | 2025 | 223583 | 0.370 |
Why?
|
Genetic Research | 1 | 2012 | 173 | 0.370 |
Why?
|
Public Opinion | 1 | 2015 | 485 | 0.360 |
Why?
|
Patient Participation | 6 | 2019 | 1446 | 0.360 |
Why?
|
Fertility | 6 | 2022 | 771 | 0.350 |
Why?
|
Mandatory Testing | 1 | 2010 | 23 | 0.350 |
Why?
|
Private Sector | 1 | 2013 | 396 | 0.340 |
Why?
|
Databases as Topic | 1 | 2012 | 472 | 0.340 |
Why?
|
Learning | 1 | 2019 | 1759 | 0.340 |
Why?
|
Aged | 51 | 2025 | 171446 | 0.330 |
Why?
|
Carcinoma | 2 | 2021 | 2330 | 0.330 |
Why?
|
Drug Industry | 3 | 2017 | 791 | 0.330 |
Why?
|
Health Behavior | 2 | 2019 | 2650 | 0.330 |
Why?
|
Perception | 2 | 2015 | 1209 | 0.330 |
Why?
|
Mammography | 2 | 2017 | 2433 | 0.320 |
Why?
|
Off-Label Use | 1 | 2010 | 185 | 0.310 |
Why?
|
Comparative Effectiveness Research | 1 | 2014 | 714 | 0.310 |
Why?
|
Health Services Accessibility | 7 | 2020 | 5520 | 0.300 |
Why?
|
Randomized Controlled Trials as Topic | 7 | 2021 | 10396 | 0.300 |
Why?
|
Medication Adherence | 9 | 2024 | 2187 | 0.300 |
Why?
|
Health Resources | 1 | 2014 | 950 | 0.300 |
Why?
|
Receptor, erbB-2 | 8 | 2023 | 2601 | 0.300 |
Why?
|
Urologic Neoplasms | 1 | 2012 | 314 | 0.300 |
Why?
|
Clinical Trials, Phase III as Topic | 2 | 2024 | 878 | 0.280 |
Why?
|
Delivery of Health Care, Integrated | 2 | 2012 | 951 | 0.280 |
Why?
|
Neoadjuvant Therapy | 6 | 2020 | 2902 | 0.270 |
Why?
|
Estrogen Receptor alpha | 2 | 2021 | 581 | 0.260 |
Why?
|
Quality of Health Care | 6 | 2018 | 4310 | 0.260 |
Why?
|
Receptors, Estrogen | 5 | 2020 | 2253 | 0.260 |
Why?
|
Endpoint Determination | 2 | 2024 | 592 | 0.260 |
Why?
|
Epidemiologic Research Design | 1 | 2009 | 368 | 0.250 |
Why?
|
Patient Acceptance of Health Care | 3 | 2018 | 3231 | 0.250 |
Why?
|
Self Efficacy | 3 | 2015 | 643 | 0.250 |
Why?
|
Resilience, Psychological | 2 | 2024 | 807 | 0.250 |
Why?
|
Attitude | 2 | 2020 | 771 | 0.240 |
Why?
|
Oxygen Consumption | 5 | 2023 | 1880 | 0.240 |
Why?
|
Charities | 1 | 2025 | 35 | 0.240 |
Why?
|
Adaptation, Psychological | 7 | 2022 | 2663 | 0.230 |
Why?
|
Topoisomerase I Inhibitors | 1 | 2024 | 70 | 0.220 |
Why?
|
Pilot Projects | 6 | 2024 | 8740 | 0.220 |
Why?
|
Mastectomy | 6 | 2024 | 1861 | 0.220 |
Why?
|
Medical Errors | 1 | 2012 | 1260 | 0.220 |
Why?
|
Patient-Centered Care | 2 | 2022 | 1444 | 0.220 |
Why?
|
Antineoplastic Combined Chemotherapy Protocols | 7 | 2024 | 11873 | 0.220 |
Why?
|
Information Dissemination | 1 | 2012 | 1142 | 0.220 |
Why?
|
Patient Selection | 4 | 2014 | 4258 | 0.220 |
Why?
|
Cost Sharing | 2 | 2017 | 409 | 0.220 |
Why?
|
United States | 24 | 2025 | 73027 | 0.210 |
Why?
|
Prospective Studies | 23 | 2024 | 54924 | 0.210 |
Why?
|
Aged, 80 and over | 24 | 2025 | 59598 | 0.210 |
Why?
|
Polymorphism, Genetic | 1 | 2013 | 4248 | 0.210 |
Why?
|
Employment | 1 | 2009 | 1110 | 0.210 |
Why?
|
Research Support as Topic | 1 | 2007 | 696 | 0.200 |
Why?
|
Societies, Medical | 7 | 2019 | 3966 | 0.200 |
Why?
|
Physicians | 5 | 2016 | 4598 | 0.200 |
Why?
|
Socioeconomic Factors | 9 | 2021 | 7851 | 0.200 |
Why?
|
Body Composition | 1 | 2011 | 2462 | 0.190 |
Why?
|
Life Style | 3 | 2021 | 3932 | 0.190 |
Why?
|
Receptors, Progesterone | 3 | 2021 | 1160 | 0.180 |
Why?
|
Ethics Committees, Research | 1 | 2022 | 196 | 0.180 |
Why?
|
Income | 4 | 2021 | 1878 | 0.180 |
Why?
|
Genotype | 9 | 2020 | 13042 | 0.180 |
Why?
|
Camptothecin | 1 | 2024 | 599 | 0.180 |
Why?
|
Certification | 1 | 2024 | 420 | 0.180 |
Why?
|
Prognosis | 9 | 2024 | 29979 | 0.180 |
Why?
|
Male | 29 | 2025 | 364641 | 0.170 |
Why?
|
Feasibility Studies | 5 | 2024 | 5314 | 0.170 |
Why?
|
Data Collection | 4 | 2014 | 3326 | 0.170 |
Why?
|
BRCA2 Protein | 2 | 2022 | 802 | 0.170 |
Why?
|
Combined Modality Therapy | 8 | 2022 | 8535 | 0.170 |
Why?
|
Publishing | 1 | 2007 | 837 | 0.170 |
Why?
|
Telemedicine | 3 | 2022 | 3109 | 0.170 |
Why?
|
Anxiety | 3 | 2023 | 4672 | 0.160 |
Why?
|
Habits | 1 | 2020 | 148 | 0.160 |
Why?
|
Social Justice | 1 | 2024 | 486 | 0.160 |
Why?
|
Neoplasm Staging | 10 | 2022 | 11221 | 0.160 |
Why?
|
Genomics | 4 | 2023 | 5925 | 0.160 |
Why?
|
Neoplasm, Residual | 1 | 2024 | 1014 | 0.160 |
Why?
|
Carcinoma, Ductal, Breast | 3 | 2020 | 1099 | 0.150 |
Why?
|
Resource Allocation | 1 | 2021 | 354 | 0.150 |
Why?
|
BRCA1 Protein | 2 | 2022 | 1155 | 0.150 |
Why?
|
Pregnancy Complications, Neoplastic | 1 | 2020 | 260 | 0.150 |
Why?
|
Health Status Disparities | 2 | 2012 | 1885 | 0.150 |
Why?
|
Receptor, Fibroblast Growth Factor, Type 1 | 1 | 2019 | 259 | 0.150 |
Why?
|
Menopause | 4 | 2017 | 1656 | 0.150 |
Why?
|
Hypertension, Pregnancy-Induced | 1 | 2023 | 529 | 0.140 |
Why?
|
Radiotherapy, Adjuvant | 3 | 2021 | 1788 | 0.140 |
Why?
|
Nontherapeutic Human Experimentation | 1 | 2017 | 22 | 0.140 |
Why?
|
Bone Marrow Transplantation | 1 | 2005 | 2710 | 0.140 |
Why?
|
Healthcare Disparities | 5 | 2017 | 3414 | 0.140 |
Why?
|
Medicare | 2 | 2015 | 6809 | 0.140 |
Why?
|
Social Support | 3 | 2024 | 2193 | 0.140 |
Why?
|
Organizational Policy | 1 | 2019 | 435 | 0.140 |
Why?
|
Palliative Care | 3 | 2020 | 3642 | 0.140 |
Why?
|
Clinical Trials, Phase I as Topic | 2 | 2022 | 329 | 0.140 |
Why?
|
Neoplastic Cells, Circulating | 1 | 2024 | 952 | 0.140 |
Why?
|
Fatigue | 2 | 2022 | 1557 | 0.130 |
Why?
|
Interviews as Topic | 1 | 2024 | 2741 | 0.130 |
Why?
|
Aromatase Inhibitors | 3 | 2015 | 519 | 0.130 |
Why?
|
Immunoconjugates | 1 | 2024 | 975 | 0.130 |
Why?
|
Patient Satisfaction | 4 | 2021 | 3488 | 0.130 |
Why?
|
Antimetabolites, Antineoplastic | 1 | 2020 | 646 | 0.130 |
Why?
|
Treatment Outcome | 14 | 2021 | 65364 | 0.130 |
Why?
|
National Cancer Institute (U.S.) | 1 | 2017 | 300 | 0.130 |
Why?
|
Carcinoma, Ductal | 1 | 2016 | 97 | 0.130 |
Why?
|
Patient Advocacy | 2 | 2024 | 362 | 0.130 |
Why?
|
Breast Feeding | 1 | 2024 | 1363 | 0.130 |
Why?
|
Health Planning | 1 | 2017 | 233 | 0.130 |
Why?
|
Communication | 5 | 2019 | 3904 | 0.130 |
Why?
|
Diphosphonates | 2 | 2012 | 634 | 0.130 |
Why?
|
Mind-Body Therapies | 3 | 2024 | 294 | 0.130 |
Why?
|
Financial Support | 2 | 2013 | 116 | 0.130 |
Why?
|
Fasting | 1 | 2022 | 1609 | 0.130 |
Why?
|
Young Adult | 15 | 2024 | 60048 | 0.120 |
Why?
|
Rural Population | 2 | 2017 | 2325 | 0.120 |
Why?
|
Delivery of Health Care | 4 | 2019 | 5366 | 0.120 |
Why?
|
Breast | 2 | 2022 | 1976 | 0.120 |
Why?
|
Gene Expression Profiling | 3 | 2019 | 9536 | 0.120 |
Why?
|
Health Priorities | 1 | 2017 | 380 | 0.120 |
Why?
|
Age Factors | 7 | 2021 | 18407 | 0.110 |
Why?
|
Patient Education as Topic | 2 | 2014 | 2336 | 0.110 |
Why?
|
Needs Assessment | 1 | 2020 | 1141 | 0.110 |
Why?
|
Stress, Psychological | 3 | 2022 | 4530 | 0.110 |
Why?
|
Organizational Affiliation | 1 | 2013 | 34 | 0.110 |
Why?
|
Hematopoiesis | 1 | 2022 | 2059 | 0.110 |
Why?
|
Reaction Time | 1 | 2019 | 2098 | 0.110 |
Why?
|
Qualitative Research | 1 | 2024 | 3140 | 0.100 |
Why?
|
Focus Groups | 1 | 2019 | 1460 | 0.100 |
Why?
|
Evidence-Based Practice | 1 | 2017 | 500 | 0.100 |
Why?
|
Health Care Surveys | 2 | 2018 | 2433 | 0.100 |
Why?
|
Ethics Committees | 1 | 2012 | 51 | 0.100 |
Why?
|
Medically Uninsured | 1 | 2017 | 840 | 0.100 |
Why?
|
Aftercare | 1 | 2018 | 916 | 0.100 |
Why?
|
Cost Savings | 2 | 2014 | 904 | 0.100 |
Why?
|
Exercise Test | 3 | 2014 | 2186 | 0.100 |
Why?
|
Disease Management | 2 | 2020 | 2533 | 0.100 |
Why?
|
Polymorphism, Single Nucleotide | 2 | 2020 | 16041 | 0.100 |
Why?
|
Research Design | 4 | 2024 | 6211 | 0.100 |
Why?
|
North Carolina | 1 | 2012 | 329 | 0.100 |
Why?
|
Evidence-Based Medicine | 3 | 2016 | 3701 | 0.100 |
Why?
|
Culture | 1 | 2015 | 622 | 0.090 |
Why?
|
Angiogenesis Inducing Agents | 1 | 2013 | 254 | 0.090 |
Why?
|
Cardiovascular Physiological Phenomena | 1 | 2013 | 239 | 0.090 |
Why?
|
Skinfold Thickness | 1 | 2011 | 164 | 0.090 |
Why?
|
Plethysmography | 1 | 2011 | 172 | 0.090 |
Why?
|
Cluster Analysis | 1 | 2018 | 2731 | 0.090 |
Why?
|
Tissue Donors | 1 | 2020 | 2381 | 0.090 |
Why?
|
Ambulatory Care | 1 | 2021 | 2781 | 0.090 |
Why?
|
Research | 2 | 2010 | 1979 | 0.090 |
Why?
|
Disclosure | 2 | 2014 | 755 | 0.090 |
Why?
|
TOR Serine-Threonine Kinases | 1 | 2019 | 2061 | 0.090 |
Why?
|
Awareness | 1 | 2014 | 653 | 0.090 |
Why?
|
Choice Behavior | 1 | 2016 | 848 | 0.090 |
Why?
|
Immunization | 1 | 2014 | 1218 | 0.090 |
Why?
|
Family | 1 | 2021 | 3210 | 0.080 |
Why?
|
Biotransformation | 1 | 2009 | 166 | 0.080 |
Why?
|
Marital Therapy | 1 | 2009 | 44 | 0.080 |
Why?
|
Educational Status | 1 | 2017 | 2515 | 0.080 |
Why?
|
Carcinoma, Lobular | 1 | 2013 | 480 | 0.080 |
Why?
|
Hematologic Neoplasms | 1 | 2021 | 1907 | 0.080 |
Why?
|
Multivariate Analysis | 3 | 2019 | 12075 | 0.080 |
Why?
|
Cyclophosphamide | 3 | 2013 | 2227 | 0.080 |
Why?
|
Live Birth | 2 | 2023 | 516 | 0.080 |
Why?
|
Germ Cells | 2 | 2022 | 644 | 0.080 |
Why?
|
Models, Economic | 2 | 2011 | 719 | 0.080 |
Why?
|
National Institutes of Health (U.S.) | 1 | 2012 | 794 | 0.080 |
Why?
|
Patient Protection and Affordable Care Act | 1 | 2018 | 1188 | 0.080 |
Why?
|
Complementary Therapies | 1 | 2012 | 487 | 0.080 |
Why?
|
Administration, Oral | 2 | 2024 | 4030 | 0.070 |
Why?
|
Conflict of Interest | 1 | 2013 | 556 | 0.070 |
Why?
|
Risk Assessment | 8 | 2018 | 24314 | 0.070 |
Why?
|
Neoplasm Metastasis | 4 | 2024 | 4904 | 0.070 |
Why?
|
Costs and Cost Analysis | 3 | 2018 | 1666 | 0.070 |
Why?
|
Radiation Oncology | 1 | 2014 | 572 | 0.070 |
Why?
|
Retrospective Studies | 7 | 2023 | 81746 | 0.070 |
Why?
|
Adjuvants, Immunologic | 2 | 2022 | 998 | 0.070 |
Why?
|
Quality Improvement | 1 | 2022 | 3855 | 0.070 |
Why?
|
Quality Indicators, Health Care | 1 | 2017 | 1805 | 0.070 |
Why?
|
Human Experimentation | 1 | 2007 | 125 | 0.070 |
Why?
|
Logistic Models | 4 | 2017 | 13289 | 0.070 |
Why?
|
Electric Impedance | 1 | 2011 | 795 | 0.070 |
Why?
|
Cohort Studies | 6 | 2024 | 41749 | 0.070 |
Why?
|
Imidazoles | 1 | 2012 | 1168 | 0.070 |
Why?
|
Vaccination | 2 | 2018 | 3437 | 0.060 |
Why?
|
Caregivers | 1 | 2018 | 2302 | 0.060 |
Why?
|
Decision Support Techniques | 1 | 2016 | 2008 | 0.060 |
Why?
|
Secondary Prevention | 1 | 2012 | 1474 | 0.060 |
Why?
|
Communicable Diseases | 1 | 2014 | 874 | 0.060 |
Why?
|
Carmustine | 1 | 2005 | 137 | 0.060 |
Why?
|
Drug Evaluation | 1 | 2007 | 642 | 0.060 |
Why?
|
Patient Care Team | 2 | 2016 | 2521 | 0.060 |
Why?
|
Health Surveys | 1 | 2015 | 4056 | 0.060 |
Why?
|
Follow-Up Studies | 5 | 2020 | 39345 | 0.060 |
Why?
|
Survival Analysis | 2 | 2008 | 10098 | 0.060 |
Why?
|
Pregnancy | 6 | 2024 | 30260 | 0.060 |
Why?
|
Guideline Adherence | 2 | 2012 | 2235 | 0.060 |
Why?
|
Premenopause | 1 | 2009 | 1039 | 0.060 |
Why?
|
Mental Health | 1 | 2019 | 3275 | 0.060 |
Why?
|
Drug Administration Schedule | 2 | 2011 | 4857 | 0.060 |
Why?
|
Drug Approval | 1 | 2012 | 820 | 0.060 |
Why?
|
Health Personnel | 1 | 2018 | 3385 | 0.060 |
Why?
|
Ovary | 1 | 2009 | 965 | 0.060 |
Why?
|
Mutation | 4 | 2023 | 30211 | 0.060 |
Why?
|
Anti-Bacterial Agents | 1 | 2023 | 7470 | 0.060 |
Why?
|
Survival Rate | 4 | 2016 | 12828 | 0.060 |
Why?
|
Cancer Vaccines | 1 | 2012 | 1041 | 0.060 |
Why?
|
Alleles | 1 | 2015 | 6894 | 0.060 |
Why?
|
DNA Topoisomerases, Type I | 1 | 2024 | 108 | 0.060 |
Why?
|
Consensus | 1 | 2014 | 3210 | 0.060 |
Why?
|
Oligonucleotide Array Sequence Analysis | 2 | 2013 | 3798 | 0.060 |
Why?
|
Authorship | 1 | 2007 | 289 | 0.060 |
Why?
|
Leukemia | 1 | 2012 | 1519 | 0.050 |
Why?
|
Multiple Myeloma | 1 | 2021 | 5196 | 0.050 |
Why?
|
Adolescent | 8 | 2024 | 89155 | 0.050 |
Why?
|
United States Food and Drug Administration | 1 | 2012 | 1671 | 0.050 |
Why?
|
Walking | 1 | 2010 | 1201 | 0.050 |
Why?
|
Protein Kinase Inhibitors | 1 | 2019 | 5694 | 0.050 |
Why?
|
Probability | 1 | 2008 | 2479 | 0.050 |
Why?
|
Phenotype | 3 | 2020 | 16723 | 0.050 |
Why?
|
Risk Factors | 7 | 2022 | 74936 | 0.050 |
Why?
|
Ontario | 1 | 2023 | 403 | 0.050 |
Why?
|
Patient Care | 1 | 2007 | 629 | 0.050 |
Why?
|
Phthalazines | 1 | 2024 | 397 | 0.050 |
Why?
|
Postmenopause | 1 | 2010 | 2518 | 0.050 |
Why?
|
Pregnancy Outcome | 2 | 2023 | 2972 | 0.050 |
Why?
|
Time Factors | 4 | 2020 | 40214 | 0.050 |
Why?
|
Fluoroquinolones | 1 | 2023 | 309 | 0.050 |
Why?
|
Ferredoxin-NADP Reductase | 1 | 2020 | 12 | 0.040 |
Why?
|
North America | 1 | 2024 | 1289 | 0.040 |
Why?
|
Reference Values | 1 | 2008 | 4938 | 0.040 |
Why?
|
Transplantation, Autologous | 1 | 2005 | 2120 | 0.040 |
Why?
|
Advisory Committees | 2 | 2016 | 797 | 0.040 |
Why?
|
Feedback | 1 | 2023 | 798 | 0.040 |
Why?
|
Cisplatin | 1 | 2005 | 1658 | 0.040 |
Why?
|
Reproducibility of Results | 2 | 2022 | 20218 | 0.040 |
Why?
|
Bipolar Disorder | 1 | 2016 | 5130 | 0.040 |
Why?
|
Pharmacies | 1 | 2021 | 171 | 0.040 |
Why?
|
Methylenetetrahydrofolate Reductase (NADPH2) | 1 | 2020 | 276 | 0.040 |
Why?
|
Oxygen | 1 | 2010 | 4269 | 0.040 |
Why?
|
Heart Failure | 1 | 2023 | 11883 | 0.040 |
Why?
|
Blood Donors | 1 | 2020 | 343 | 0.040 |
Why?
|
Patient Compliance | 2 | 2021 | 2697 | 0.040 |
Why?
|
Academies and Institutes | 1 | 2020 | 326 | 0.040 |
Why?
|
Cell Adhesion Molecules | 1 | 2024 | 1613 | 0.040 |
Why?
|
Health Promotion | 1 | 2010 | 2210 | 0.040 |
Why?
|
Lung | 1 | 2016 | 10094 | 0.040 |
Why?
|
Class I Phosphatidylinositol 3-Kinases | 1 | 2022 | 904 | 0.040 |
Why?
|
Cancer Care Facilities | 1 | 2020 | 427 | 0.040 |
Why?
|
Pregnancy Rate | 1 | 2020 | 655 | 0.040 |
Why?
|
Prescription Fees | 1 | 2018 | 153 | 0.030 |
Why?
|
Insurance Coverage | 2 | 2018 | 1946 | 0.030 |
Why?
|
Doxorubicin | 2 | 2013 | 2234 | 0.030 |
Why?
|
Anthracyclines | 1 | 2018 | 286 | 0.030 |
Why?
|
Antigens, Neoplasm | 1 | 2024 | 1997 | 0.030 |
Why?
|
Immunotherapy | 1 | 2012 | 4748 | 0.030 |
Why?
|
Heterozygote | 1 | 2022 | 2798 | 0.030 |
Why?
|
Genetic Testing | 1 | 2009 | 3589 | 0.030 |
Why?
|
Adenocarcinoma | 1 | 2013 | 6371 | 0.030 |
Why?
|
Attitude to Health | 1 | 2004 | 2024 | 0.030 |
Why?
|
Body Image | 1 | 2020 | 646 | 0.030 |
Why?
|
Gene Expression | 1 | 2008 | 7597 | 0.030 |
Why?
|
Confidence Intervals | 1 | 2020 | 2923 | 0.030 |
Why?
|
Proportional Hazards Models | 1 | 2009 | 12536 | 0.030 |
Why?
|
Age Distribution | 1 | 2020 | 2871 | 0.030 |
Why?
|
Antibiotics, Antineoplastic | 1 | 2018 | 681 | 0.030 |
Why?
|
Gene Amplification | 1 | 2019 | 1088 | 0.030 |
Why?
|
Odds Ratio | 2 | 2020 | 9666 | 0.030 |
Why?
|
Adjuvants, Pharmaceutic | 1 | 2014 | 48 | 0.030 |
Why?
|
Case-Control Studies | 2 | 2013 | 22287 | 0.030 |
Why?
|
Psychotherapy | 1 | 2023 | 1655 | 0.030 |
Why?
|
Dose-Response Relationship, Drug | 1 | 2005 | 10757 | 0.030 |
Why?
|
Chromosomes, Human, Pair 21 | 1 | 1993 | 228 | 0.030 |
Why?
|
Genital Neoplasms, Female | 1 | 2018 | 536 | 0.030 |
Why?
|
Immunocompromised Host | 1 | 2018 | 863 | 0.030 |
Why?
|
Chromosomes, Human, Pair 14 | 1 | 1993 | 285 | 0.030 |
Why?
|
Genes, BRCA2 | 1 | 2016 | 593 | 0.030 |
Why?
|
Placebos | 1 | 2017 | 1667 | 0.030 |
Why?
|
Genome-Wide Association Study | 1 | 2012 | 12795 | 0.030 |
Why?
|
Virus Diseases | 1 | 2018 | 723 | 0.030 |
Why?
|
Genes, BRCA1 | 1 | 2016 | 755 | 0.030 |
Why?
|
Depression | 2 | 2023 | 8231 | 0.020 |
Why?
|
Tissue and Organ Procurement | 1 | 2020 | 986 | 0.020 |
Why?
|
Analysis of Variance | 1 | 2020 | 6228 | 0.020 |
Why?
|
Weight Gain | 1 | 2022 | 2359 | 0.020 |
Why?
|
Models, Theoretical | 1 | 2004 | 3573 | 0.020 |
Why?
|
Lymphedema | 1 | 2018 | 527 | 0.020 |
Why?
|
Lymphatic Metastasis | 1 | 2019 | 2908 | 0.020 |
Why?
|
Germ-Line Mutation | 1 | 2020 | 1883 | 0.020 |
Why?
|
Body Weight | 1 | 2022 | 4628 | 0.020 |
Why?
|
Behavior | 1 | 2014 | 541 | 0.020 |
Why?
|
Mammaplasty | 1 | 2021 | 1268 | 0.020 |
Why?
|
Cost Control | 1 | 2013 | 627 | 0.020 |
Why?
|
Terminology as Topic | 1 | 2018 | 1542 | 0.020 |
Why?
|
Health Policy | 2 | 2011 | 2698 | 0.020 |
Why?
|
Tumor Burden | 1 | 2017 | 1904 | 0.020 |
Why?
|
Weight Loss | 1 | 2022 | 2721 | 0.020 |
Why?
|
Algorithms | 1 | 2011 | 14163 | 0.020 |
Why?
|
Comprehension | 1 | 2016 | 639 | 0.020 |
Why?
|
Postoperative Care | 1 | 2017 | 1480 | 0.020 |
Why?
|
Bacterial Infections | 1 | 2018 | 1397 | 0.020 |
Why?
|
Immunoenzyme Techniques | 1 | 2013 | 1698 | 0.020 |
Why?
|
Cognition | 1 | 2007 | 7072 | 0.020 |
Why?
|
Radiotherapy Dosage | 1 | 2017 | 2916 | 0.020 |
Why?
|
Incidence | 1 | 2008 | 21532 | 0.020 |
Why?
|
Personal Satisfaction | 1 | 2014 | 643 | 0.020 |
Why?
|
Health Services Misuse | 1 | 2011 | 246 | 0.020 |
Why?
|
Longitudinal Studies | 2 | 2018 | 14783 | 0.020 |
Why?
|
Predictive Value of Tests | 2 | 2016 | 15442 | 0.020 |
Why?
|
Genes | 1 | 1993 | 1824 | 0.020 |
Why?
|
Tumor Suppressor Protein p53 | 1 | 2019 | 2953 | 0.020 |
Why?
|
Piperazines | 1 | 2019 | 2552 | 0.020 |
Why?
|
Safety | 1 | 2013 | 1159 | 0.020 |
Why?
|
Sick Role | 1 | 2009 | 229 | 0.020 |
Why?
|
Physical Fitness | 1 | 2013 | 744 | 0.020 |
Why?
|
Forecasting | 1 | 2017 | 2945 | 0.020 |
Why?
|
Developing Countries | 1 | 2021 | 2913 | 0.020 |
Why?
|
Lymph Nodes | 1 | 2019 | 3472 | 0.020 |
Why?
|
Boston | 1 | 2021 | 9368 | 0.020 |
Why?
|
Guidelines as Topic | 1 | 2014 | 1395 | 0.020 |
Why?
|
Beneficence | 1 | 2007 | 56 | 0.020 |
Why?
|
Australia | 1 | 2011 | 1265 | 0.020 |
Why?
|
Massachusetts | 1 | 2021 | 8888 | 0.020 |
Why?
|
Exercise Tolerance | 1 | 2013 | 846 | 0.020 |
Why?
|
Cell Line, Tumor | 1 | 2024 | 17128 | 0.020 |
Why?
|
Standard of Care | 1 | 2012 | 568 | 0.020 |
Why?
|
Pyridines | 1 | 2019 | 2893 | 0.020 |
Why?
|
Pain | 1 | 2022 | 5100 | 0.020 |
Why?
|
Amyloid beta-Protein Precursor | 1 | 1993 | 1117 | 0.020 |
Why?
|
Child | 3 | 2022 | 80906 | 0.020 |
Why?
|
Cardiovascular Diseases | 1 | 2013 | 15660 | 0.020 |
Why?
|
Cardiovascular System | 1 | 2014 | 841 | 0.020 |
Why?
|
Stress Disorders, Post-Traumatic | 1 | 2024 | 4640 | 0.020 |
Why?
|
Reverse Transcriptase Polymerase Chain Reaction | 1 | 2013 | 4576 | 0.020 |
Why?
|
Genetic Association Studies | 1 | 2015 | 2744 | 0.020 |
Why?
|
Ventricular Function, Left | 1 | 2018 | 3941 | 0.020 |
Why?
|
Genetic Predisposition to Disease | 2 | 2022 | 18062 | 0.020 |
Why?
|
Europe | 1 | 2011 | 3437 | 0.010 |
Why?
|
Stroke Volume | 1 | 2018 | 5624 | 0.010 |
Why?
|
Inflammation Mediators | 1 | 2013 | 1892 | 0.010 |
Why?
|
Drug Resistance, Neoplasm | 1 | 2019 | 5335 | 0.010 |
Why?
|
Health Services Research | 1 | 2011 | 1815 | 0.010 |
Why?
|
Depressive Disorder | 1 | 2016 | 3721 | 0.010 |
Why?
|
Education, Medical | 1 | 1995 | 1742 | 0.010 |
Why?
|
Referral and Consultation | 1 | 2016 | 3619 | 0.010 |
Why?
|
Infant, Newborn | 1 | 2023 | 26420 | 0.010 |
Why?
|
Neovascularization, Pathologic | 1 | 2013 | 2630 | 0.010 |
Why?
|
Goals | 1 | 2007 | 717 | 0.010 |
Why?
|
Health Care Reform | 1 | 2011 | 1256 | 0.010 |
Why?
|
Curriculum | 1 | 1995 | 3782 | 0.010 |
Why?
|
Oxidative Stress | 1 | 2013 | 3140 | 0.010 |
Why?
|
Alzheimer Disease | 2 | 1993 | 8761 | 0.010 |
Why?
|
Diagnosis, Differential | 1 | 2016 | 13000 | 0.010 |
Why?
|
Endothelium, Vascular | 1 | 2013 | 4427 | 0.010 |
Why?
|
Attention Deficit Disorder with Hyperactivity | 1 | 2016 | 3729 | 0.010 |
Why?
|
Electrocardiography | 1 | 2014 | 6411 | 0.010 |
Why?
|
Stem Cells | 1 | 2013 | 3537 | 0.010 |
Why?
|
Motivation | 1 | 2009 | 2020 | 0.010 |
Why?
|
RNA, Messenger | 1 | 2013 | 12797 | 0.010 |
Why?
|
Carcinoma, Non-Small-Cell Lung | 1 | 2016 | 5394 | 0.010 |
Why?
|
Hospitalization | 1 | 2016 | 10840 | 0.010 |
Why?
|
Diet | 1 | 2014 | 8087 | 0.010 |
Why?
|
Risk | 1 | 2004 | 9609 | 0.010 |
Why?
|
Lung Neoplasms | 1 | 2016 | 13499 | 0.010 |
Why?
|
Chromosomes, Human | 1 | 1993 | 437 | 0.010 |
Why?
|
Genetic Linkage | 1 | 1993 | 2342 | 0.000 |
Why?
|
Genetic Markers | 1 | 1993 | 2602 | 0.000 |
Why?
|
Pedigree | 1 | 1993 | 4539 | 0.000 |
Why?
|
Chromosome Mapping | 1 | 1993 | 4618 | 0.000 |
Why?
|
Models, Biological | 1 | 1993 | 9493 | 0.000 |
Why?
|